Series | Jotup

Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines

Retrieved on:

Thursday, March 21, 2024

Angelini, Biotechnology, Immunotherapy, Affirmative action, Patient, Digital health, Hereditary nonpolyposis colorectal cancer, Cancer, Series, Merck Group, Pharmaceutical industry

Angelini Ventures’ investment of €7 million brings the total raised by Nouscom, in its oversubscribed Series C round – first announced in November 2023 – to €75.8 million (approx.

Key Points:

Angelini Ventures’ investment of €7 million brings the total raised by Nouscom, in its oversubscribed Series C round – first announced in November 2023 – to €75.8 million (approx.
Our aim is to promote innovation by investing in a portfolio of high-quality companies in Europe and North America that are transforming healthcare to improve patient outcomes.
Our investment in Nouscom is a great example of the type of company we are interested in.
This kind of investment fully responds to our long-term vision which is to take care of patients, communities, and nations, aiming to transform the future of the global health system.”

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Retrieved on:

Monday, March 18, 2024

Committee, Partnership, SAN, Viking Global Investors, Doctor of Philosophy, Standard BioTools, Standard, Series, Security (finance)

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin").

Key Points:

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin").
Thomas Carey, Chairman of the Standard BioTools Board of Directors, said, “We are pleased to reach this agreement with Viking and Casdin.
This exchange price resulted in the issuance of approximately 17.8 million additional shares of common stock, as compared to the shares of common stock issuable under the Series B Preferred’s stated $3.40 per share conversion price.
As a result, the Company now has approximately 382.5 million shares of common stock outstanding.

American Rebel Announces $19.9+ Million Public 8.53% Preferred Offering - Updated

Retrieved on:

Friday, March 15, 2024

Freedom, Public, Offering, VIP, Digital, Regulation, Love, Security, Series

Nashville, TN, March 15, 2024 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), is pleased to announce the launch of a Regulation A+, equity financing of up to $19,999,995 of 8.53% Series C Redeemable Convertible Preferred Stock (the “Public Offering”).

Key Points:

Nashville, TN, March 15, 2024 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), is pleased to announce the launch of a Regulation A+, equity financing of up to $19,999,995 of 8.53% Series C Redeemable Convertible Preferred Stock (the “Public Offering”).
This Public Offering is a watershed event for the Company and allows anyone 18 years or older to log onto the American Rebel Public Offering website at https://invest.americanrebel.com/ and with a click of a button subscribe to the offering.
A copy of the Company’s offering circular for the Public Offering has been posted at https://www.sec.gov/Archives/edgar/data/1648087/000149315224009903/form2... .
Andy Ross, Chief Executive Officer of American Rebel, commented, “American Rebel is America’s Patriotic brand.

American Rebel Announces $19.9+ Million Public 8.53% Preferred Offering

Retrieved on:

Friday, March 15, 2024

Freedom, Public, Offering, VIP, Digital, Regulation, Love, Security, Series

Nashville, TN, March 15, 2024 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), is pleased to announce the launch of a Regulation A+, equity financing of up to $19,999,995 of 8.53% Series C Redeemable Convertible Preferred Stock (the “Public Offering”).

Key Points:

Nashville, TN, March 15, 2024 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), is pleased to announce the launch of a Regulation A+, equity financing of up to $19,999,995 of 8.53% Series C Redeemable Convertible Preferred Stock (the “Public Offering”).
This Public Offering is a watershed event for the Company and allows anyone 18 years or older to log onto the American Rebel Public Offering website at https://invest.americanrebel.com/ and with a click of a button subscribe to the offering.
A copy of the Company’s offering circular for the Public Offering has been posted at https://www.sec.gov/Archives/edgar/data/1648087/000149315224009903/form2... .
Andy Ross, Chief Executive Officer of American Rebel, commented, “American Rebel is America’s Patriotic brand.

Clique raises $8M in Series A to revolutionize the way smart contracts access data

Retrieved on:

Thursday, March 14, 2024

This latest funding round aims to power Clique's mission of enabling efficient and optimal compute resource allocation for applications that have different preferences.

Key Points:

This latest funding round aims to power Clique's mission of enabling efficient and optimal compute resource allocation for applications that have different preferences.
To date, Clique has enabled over US$3,500,000,000 in on-chain transactions through the use of their protocol.
The Clique Compute Coordination Network organizes various off-chain compute resources, allocating them as needed by both general applications and smart contracts.
This allows applications to access different compute resources and data easily, with the ability to adjust for preferences around trust, privacy, performance, and cost.

Textainer Closes Acquisition by Stonepeak and Announces Post-Acquisition Redemption of All Preference Shares and Related Depositary Shares

Retrieved on:

Thursday, March 14, 2024

Certification, Exchange, Textainer Group Holdings, TGH, CUSIP, Acquisition, Series, Security (finance)

Also on March 14, 2024, after the closing of the acquisition, Textainer issued a notice of redemption for all its (i) 7.000% Series A Cumulative Redeemable Perpetual Preference Shares (the “Series A Preference Shares”) and the corresponding redemption of each depositary share representing a 1/1000th interest in each such share, CUSIP 88314W204 (NYSE: TGH PRA) (the “Series A Depositary Shares”), and (ii) 6.250% Series B Cumulative Redeemable Perpetual Preference Shares (the “Series B Preference Shares” and, collectively with the Series A Preference Shares, the “Preference Shares”) and the corresponding redemption of each depositary share representing a 1/1000th interest in each such share, CUSIP 88314W303 (NYSE: TGH PRB) (the “Series B Depositary Shares”).

Key Points:

Also on March 14, 2024, after the closing of the acquisition, Textainer issued a notice of redemption for all its (i) 7.000% Series A Cumulative Redeemable Perpetual Preference Shares (the “Series A Preference Shares”) and the corresponding redemption of each depositary share representing a 1/1000th interest in each such share, CUSIP 88314W204 (NYSE: TGH PRA) (the “Series A Depositary Shares”), and (ii) 6.250% Series B Cumulative Redeemable Perpetual Preference Shares (the “Series B Preference Shares” and, collectively with the Series A Preference Shares, the “Preference Shares”) and the corresponding redemption of each depositary share representing a 1/1000th interest in each such share, CUSIP 88314W303 (NYSE: TGH PRB) (the “Series B Depositary Shares”).
The redemption date for the Preference Shares and corresponding depositary shares will be April 15, 2024 (the “Redemption Date”).
No dividends on the Preference Shares and depositary shares will accrue on or after the Redemption Date, nor will any interest accrue on amounts held to pay the redemption price.
Following the redemption of the Preference Shares and depositary shares, Textainer will request that the NYSE delist the depositary shares.

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

Retrieved on:

Thursday, March 14, 2024

Conference, Webcast, Patient, Common, Fats, GI, Acquisition, First wave, NIH, Gastrointestinal disease, Series, Marketing, Gastroparesis, FDA, Cystic fibrosis, Food, Digestion, Pharmaceutical industry

BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease. James Sapirstein will continue to serve as Chairman and Chief Executive Officer of First Wave BioPharma with Jack Syage, Ph.D., previously the Chief Executive Officer and Co-Founder of ImmunogenX, assuming the role of President and Chief Operating Officer of First Wave BioPharma. Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.

Key Points:

Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.
First Wave BioPharma intends to license the commercial rights to latiglutenase in the United States and Canada to a strategic global pharmaceutical company which will commercialize latiglutenase following receipt of marketing approval.
First Wave BioPharma will also seek to secure financing commitments from a syndicate of institutional healthcare investors to fund the ongoing development of latiglutenase.
First Wave BioPharma will host a conference call and live audio webcast today, March 14, 2024, at 8:30 a.m.

Esports Entertainment Group Announces Secured Note and Amendments to its Convertible Preferred Stock

Retrieved on:

Wednesday, March 13, 2024

OTC Markets Group, Growth, Business, Holder, Series, Calendar, Security (finance)

St. Julian’s, Malta, March 13, 2024 (GLOBE NEWSWIRE) -- Esports Entertainment Group, Inc. (OTC Pink: GMBL) (OTC Pink: GMBLP) (OTC Pink: GMBLW) (OTC Pink: GMBLZ) (“Esports Entertainment”, “EEG”, or the “Company”), a leading, global iGaming company and business-to-business (B2B) esports content and solutions provider, today announced it has entered into a note purchase agreement, dated March 7, 2024, with the holder (the “Holder”) of its Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, pursuant to which the Company issued the Holder a secured promissory note (the “Secured Note”) for approximately $1.42 million in cash and certain amendments to the terms of the Series C Convertible Preferred Stock and Series Convertible D Preferred Stock, repayable in 2 years with an interest rate of 10% per annum recorded in-kind by adding the amount of accrued interest to the outstanding principal balance of the Secured Note on the last Business Day of each calendar quarter.

Key Points:

St. Julian’s, Malta, March 13, 2024 (GLOBE NEWSWIRE) -- Esports Entertainment Group, Inc. (OTC Pink: GMBL) (OTC Pink: GMBLP) (OTC Pink: GMBLW) (OTC Pink: GMBLZ) (“Esports Entertainment”, “EEG”, or the “Company”), a leading, global iGaming company and business-to-business (B2B) esports content and solutions provider, today announced it has entered into a note purchase agreement, dated March 7, 2024, with the holder (the “Holder”) of its Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, pursuant to which the Company issued the Holder a secured promissory note (the “Secured Note”) for approximately $1.42 million in cash and certain amendments to the terms of the Series C Convertible Preferred Stock and Series Convertible D Preferred Stock, repayable in 2 years with an interest rate of 10% per annum recorded in-kind by adding the amount of accrued interest to the outstanding principal balance of the Secured Note on the last Business Day of each calendar quarter.
The amendments to the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock Certificate of Designations include a six month standstill on certain conversions, limits to conversions thereafter, freeze on dividends for two years through the new maturity date of March 7, 2026, and an allowance for the Company to raise up to $10 million that could be used for other operational purposes and not for repayment of the preferred stock.
At the moment, we are firmly focused on continuing to reduce corporate expenses while simultaneously driving growth and profitability.
The Secured Note provides us greater financial flexibility, as we continue to reduce costs, improve our balance sheet, enhance our cash flow, and execute on our growth initiatives within the iGaming, venue management and e-simulator markets.

Artesian Resources Corporation Reports 2023 Year-End Earnings and Fourth Quarter Results

Retrieved on:

Wednesday, March 13, 2024

Tax, Information technology, PFAS, Delmarva Peninsula, ACB, CoBank, Depreciation, Overalls, SLP, Investment, Water, Series, Delaware Public Service Commission, Drinking water, Ageing, Real estate

NEWARK, Del., March 13, 2024 (GLOBE NEWSWIRE) -- Artesian Resources Corporation (Nasdaq: ARTNA), a leading provider of water and wastewater services, and related services, on the Delmarva Peninsula, today announced earnings results for the fourth quarter and year ended December 31, 2023.

Key Points:

NEWARK, Del., March 13, 2024 (GLOBE NEWSWIRE) -- Artesian Resources Corporation (Nasdaq: ARTNA), a leading provider of water and wastewater services, and related services, on the Delmarva Peninsula, today announced earnings results for the fourth quarter and year ended December 31, 2023.
The primary refund calculation for both 2023 and 2022 was based on the average loan balance outstanding.
“In April 2023 we filed a request for an increase in water rates in our Delaware operations.
Federal and state income tax expense increased $0.3 million, or 32.4%, primarily due to higher pre-tax income in 2023 compared to 2022.

Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on:

Tuesday, March 12, 2024

Exercise, H-1, Sale, Intelligence, H-2, Ladenburg Thalmann, Series, Calendar, FDA, Food, Security (finance)

The gross proceeds to INBS from the private placement were approximately $10.1 million, before deducting placement agent fees and other offering expenses payable by the Company.

Key Points:

The gross proceeds to INBS from the private placement were approximately $10.1 million, before deducting placement agent fees and other offering expenses payable by the Company.
The Series H-1 warrants and Series H-2 warrants have an exercise price of $4.55 per share of common stock and are exercisable immediately upon issuance.
The Series H-1 warrants have a term of eighteen months following the date a registration statement registering all warrant shares underlying the Series H-1 warrants is declared effective by the United States Securities and Exchange Commission (“SEC”).
Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.